Trevi Therapeutics, Inc. - Common Stock (TRVI)
CUSIP: 89532M101
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 128,120,714
- Total 13F shares
- 114,653,135
- Share change
- +26,497,472
- Total reported value
- $627,154,153
- Put/Call ratio
- 39%
- Price per share
- $5.47
- Number of holders
- 153
- Value change
- +$139,569,505
- Number of buys
- 103
- Number of sells
- 54
Quarterly Holders Quick Answers
What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89532M101:
Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| NEA Management Company, LLC |
13F
|
Company |
8.9%
|
11,370,376
|
$71,519,665 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
8%
|
10,259,409
|
$64,531,683 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
4.1%
|
5,312,542
|
$33,415,888 | — | 31 Mar 2025 | |
| Rubric Capital Management LP |
13F
|
Company |
3.5%
|
4,538,535
|
$28,547,385 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3%
|
3,838,032
|
$24,141,221 | — | 31 Mar 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
2.7%
|
3,487,903
|
$21,938,910 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
2.7%
|
3,428,366
|
$21,564,422 | — | 31 Mar 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.6%
|
3,322,000
|
$20,895,380 | — | 31 Mar 2025 | |
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
2.5%
|
3,227,792
|
$20,302,812 | — | 31 Mar 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
2.3%
|
2,988,000
|
$18,794,520 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.2%
|
2,863,793
|
$18,013,258 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
2%
|
2,554,221
|
$16,066,051 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
1.8%
|
2,368,005
|
$14,894,754 | — | 31 Mar 2025 | |
| ACORN CAPITAL ADVISORS, LLC |
13F
|
Company |
1.7%
|
2,144,844
|
$13,491,069 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.6%
|
2,057,812
|
$12,943,637 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
1.4%
|
1,758,619
|
$11,061,714 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,614,865
|
$10,159,864 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.1%
|
1,424,506
|
$8,960,143 | — | 31 Mar 2025 | |
| MAI Capital Management |
13F
|
Company |
1.1%
|
1,385,050
|
$8,711,965 | — | 31 Mar 2025 | |
| Venrock Healthcare Capital Partners II, L.P. |
13D/G
|
— |
1.4%
|
1,266,457
|
$8,042,002 | $0 | 31 Dec 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.98%
|
1,250,000
|
$7,862,500 | — | 31 Mar 2025 | |
| TPG GP A, LLC |
3/4/5
|
Former 10% Owner |
—
class O/S missing
|
3,824,883
|
$7,726,264 | — | 01 Jul 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.87%
|
1,120,000
|
$7,044,800 | — | 31 Mar 2025 | |
| Rosalind Advisors, Inc. |
13D/G
13F
|
Company |
1.2%
|
1,062,500
|
$6,746,875 | $0 | 13 Feb 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.67%
|
852,985
|
$5,365,275 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.64%
|
823,249
|
$5,178,236 | — | 31 Mar 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
0.62%
|
795,000
|
$5,000,550 | — | 31 Mar 2025 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.61%
|
785,961
|
$4,943,695 | — | 31 Mar 2025 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.54%
|
686,219
|
$4,316,318 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
0.48%
|
615,506
|
$3,871,533 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.45%
|
575,000
|
$3,616,749 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.44%
|
566,197
|
$3,561,379 | — | 31 Mar 2025 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.43%
|
550,919
|
$3,465,281 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.41%
|
530,000
|
$3,333,700 | — | 31 Mar 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.4%
|
509,379
|
$3,203,994 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.39%
|
494,567
|
$3,110,826 | — | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.34%
|
440,000
|
$2,767,600 | — | 31 Mar 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.33%
|
424,715
|
$2,671,457 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.27%
|
340,164
|
$2,139,632 | — | 31 Mar 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.27%
|
339,904
|
$2,137,996 | — | 31 Mar 2025 | |
| Peter W. Sonsini |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
3,948,948
mixed-class rows
|
$1,916,875 | — | 11 Apr 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.22%
|
281,099
|
$1,768,113 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.21%
|
273,620
|
$1,721,069 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.17%
|
211,873
|
$1,332,682 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.16%
|
207,518
|
$1,305,288 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.16%
|
206,962
|
$1,301,788 | — | 31 Mar 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.16%
|
201,107
|
$1,264,963 | — | 31 Mar 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.14%
|
180,000
|
$1,132,200 | — | 31 Mar 2025 | |
| Tejara Capital Ltd |
13F
|
Company |
0.14%
|
179,516
|
$1,129,156 | — | 31 Mar 2025 | |
| STATE OF WISCONSIN INVESTMENT BOARD |
13F
|
Company |
0.14%
|
175,145
|
$1,101,662 | — | 31 Mar 2025 |
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock (TRVI) as of Q2 2025
As of 30 Jun 2025,
Trevi Therapeutics, Inc. - Common Stock (TRVI) was held by
153 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
114,653,135 shares.
The largest 10 holders included
NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, BlackRock, Inc., VANGUARD GROUP INC, Vivo Capital, LLC, ALLIANCEBERNSTEIN L.P., Woodline Partners LP, Siren, L.L.C., and Octagon Capital Advisors LP.
This page lists
153
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
137
Q2 2025 holders
153
Holder diff
16
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.